Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **mitochondria-mediated apoptotic pathway** (also called the intrinsic or mitochondrial pathway of apoptosis) is a fundamental **cell death signaling pathway** that is activated in response to intracellular stressors such as DNA damage, hypoxia, oxidative stress, and deprivation of growth factors[1][2][7]. It involves a series of tightly regulated molecular events leading to mitochondrial outer membrane permeabilization (MOMP), primarily controlled by the balance between pro-apoptotic (BAX, BAK) and anti-apoptotic (Bcl-2, Bcl-XL) **Bcl-2 family proteins**[1][3][4][5]. Upon MOMP, mitochondria release apoptogenic factors including **cytochrome c**, which binds Apaf-1 and ATP/dATP to form the **apoptosome**, leading to activation of initiator caspase-9, and subsequently executioner caspases (e.g., caspase-3 and -7)[1][2][5][6]. Additional factors released include SMAC/DIABLO and OMI/HtrA2, which antagonize inhibitors of apoptosis (IAPs)[6]. Dysregulation of this pathway is central to the pathogenesis of cancers (where it is frequently inhibited), neurodegenerative diseases, and other forms of tissue injury[2][4][5]. The pathway itself is a **signaling mechanism**, not a discrete molecule or receptor, and thus is not a therapeutic target in the sense of being an individual protein or receptor; rather, specific molecular components of the pathway (e.g., BCL-2, BAX) are therapeutic targets[1][3][5][7]. The term "mitochondria-mediated apoptotic pathway" refers to a process, not a single gene or protein, and should not be treated as a canonical therapeutic target or biomolecule. For structured target annotation purposes, one should instead reference specific components (such as "B-cell lymphoma 2" or "BAX protein").
Induction of mitochondrial outer membrane permeabilization (MOMP); Inhibition of anti-apoptotic Bcl-2 proteins to trigger cytochrome c release and caspase activation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondria-mediated apoptotic pathway.